Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management.
作者信息
Lopez Salvatore, Zeybek Burak, Santin Alessandro D
机构信息
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA.
出版信息
Oncotarget. 2018 Nov 30;9(94):36652-36653. doi: 10.18632/oncotarget.26413.
Abstract
摘要
相似文献
1
Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management.针对子宫浆液性癌中的人表皮生长因子受体2/神经（HER2/neu）：治疗模式的转变。
Oncotarget. 2018 Nov 30;9(94):36652-36653. doi: 10.18632/oncotarget.26413.
2
Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma.选择HER2/NEU阴性肿瘤细胞作为子宫浆液性癌对曲妥珠单抗耐药的一种机制。
Gynecol Oncol Rep. 2020 Feb 25;32:100554. doi: 10.1016/j.gore.2020.100554. eCollection 2020 May.
3
Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.奈拉替尼与奥拉帕利联合用于过表达HER2/neu的子宫浆液性癌的协同活性。
Gynecol Oncol. 2022 Aug;166(2):351-357. doi: 10.1016/j.ygyno.2022.05.021. Epub 2022 May 28.
4
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab.子宫浆液性癌中 Her2/neu 细胞外结构域脱落：曲妥珠单抗免疫治疗的意义。
Br J Cancer. 2011 Oct 11;105(8):1176-82. doi: 10.1038/bjc.2011.369. Epub 2011 Sep 13.
5
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.SYD985，一种新型的基于多卡霉素的靶向HER2的抗体药物偶联物，在表达HER2/Neu的子宫浆液性癌中显示出抗肿瘤活性。
Mol Cancer Ther. 2016 Aug;15(8):1900-9. doi: 10.1158/1535-7163.MCT-16-0163. Epub 2016 Jun 2.
6
Narrative review on the evolving role of HER2/neu targeting in uterine serous cancers.关于HER2/neu靶向治疗在子宫浆液性癌中不断演变作用的叙述性综述。
Ann Transl Med. 2024 Aug 1;12(4):69. doi: 10.21037/atm-23-1465. Epub 2023 Nov 9.
7
Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.siRNA 下调膜补体抑制剂 CD55 和 CD59 使过度表达 Her2/neu 的子宫浆液性癌对补体和抗体依赖性细胞细胞毒性敏感：对曲妥珠单抗为基础的免疫治疗的影响。
Br J Cancer. 2012 Apr 24;106(9):1543-50. doi: 10.1038/bjc.2012.132.
8
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.阿法替尼在体外和体内均显示出对HER2扩增的子宫浆液性子宫内膜癌具有显著活性。
Br J Cancer. 2014 Oct 28;111(9):1750-6. doi: 10.1038/bjc.2014.519. Epub 2014 Sep 30.
9
Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo.奈拉替尼在体外和体内显示出治疗 HER2/neu 扩增的子宫浆液性癌的疗效。
Gynecol Oncol. 2014 Oct;135(1):142-8. doi: 10.1016/j.ygyno.2014.08.006. Epub 2014 Aug 12.
10
Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.达可替尼（PF-00299804）是一种第二代不可逆泛erbB受体酪氨酸激酶抑制剂，在体外对HER2扩增的子宫浆液性子宫内膜癌显示出显著活性。
Tumour Biol. 2015 Jul;36(7):5505-13. doi: 10.1007/s13277-015-3218-4. Epub 2015 Feb 11.
引用本文的文献
1
Role of signaling pathways in endometrial cancer.信号通路在子宫内膜癌中的作用。
Mol Biol Rep. 2025 Apr 21;52(1):408. doi: 10.1007/s11033-025-10523-1.
2
Assessment of Cyclin D1 Expression: Prognostic Value and Functional Insights in Endometrial Cancer: In Silico Study.细胞周期蛋白D1表达的评估：子宫内膜癌的预后价值和功能见解：计算机模拟研究
Int J Mol Sci. 2025 Jan 22;26(3):890. doi: 10.3390/ijms26030890.
3
An Overview of Endometrial Cancer with Novel Therapeutic Strategies.子宫内膜癌的治疗新策略概述。
Curr Oncol. 2023 Aug 27;30(9):7904-7919. doi: 10.3390/curroncol30090574.
本文引用的文献
1
2
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.随机Ⅱ期临床试验：卡铂-紫杉醇对比卡铂-紫杉醇-曲妥珠单抗治疗人表皮生长因子受体 2/neu 过表达的子宫浆液性癌。
J Clin Oncol. 2018 Jul 10;36(20):2044-2051. doi: 10.1200/JCO.2017.76.5966. Epub 2018 Mar 27.
3
Cancer statistics, 2018.癌症统计数据，2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
4
Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice.针对子宫内膜浆液性癌的 HER2 检测标准化：大型学术中心的 4 年经验及临床实践建议。
Mod Pathol. 2013 Dec;26(12):1605-12. doi: 10.1038/modpathol.2013.113. Epub 2013 Jun 14.
5
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.子宫浆液性癌中体细胞单核苷酸和拷贝数突变的全景
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28.
6
Letter to the Editor referring to the manuscript entitled: "Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study" recently reported by Fleming et al., (Gynecol Oncol., 116;15-20;2010).致编辑的信，涉及弗莱明等人最近报道的题为《曲妥珠单抗治疗晚期或复发性HER阳性子宫内膜癌女性的II期试验：妇科肿瘤学组研究》的手稿（《妇科肿瘤学》，第116卷，第15 - 20页；2010年）
Gynecol Oncol. 2010 Jul;118(1):95-6; author reply 96-7. doi: 10.1016/j.ygyno.2010.01.043. Epub 2010 Feb 20.
7
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.曲妥珠单抗治疗晚期或复发性HER2阳性子宫内膜癌女性的II期试验：一项妇科肿瘤学组研究
Gynecol Oncol. 2010 Jan;116(1):15-20. doi: 10.1016/j.ygyno.2009.09.025. Epub 2009 Oct 18.
8
Overexpression of HER-2/neu in uterine serous papillary cancer.HER-2/neu在子宫浆液性乳头状癌中的过表达。
Clin Cancer Res. 2002 May;8(5):1271-9.
9
Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women.乳头状浆液性和透明细胞型导致黑人女性子宫内膜癌预后不良。
Gynecol Oncol. 1997 May;65(2):206-12. doi: 10.1006/gyno.1997.4617.
Zotero 插件